A detailed history of Vestor Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Vestor Capital, LLC holds 362 shares of VRTX stock, worth $147,761. This represents 0.01% of its overall portfolio holdings.

Number of Shares
362
Previous 311 16.4%
Holding current value
$147,761
Previous $146,000 15.07%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$460.0 - $505.78 $23,460 - $25,794
51 Added 16.4%
362 $168,000
Q2 2024

Jul 30, 2024

BUY
$392.81 - $485.53 $22,390 - $27,675
57 Added 22.44%
311 $146,000
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $815 - $892
-2 Reduced 0.78%
254 $106,000
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $8,575 - $10,267
25 Added 10.82%
256 $104,000
Q3 2023

Nov 08, 2023

SELL
$338.18 - $362.46 $66,621 - $71,404
-197 Reduced 46.03%
231 $80,000
Q2 2023

Aug 21, 2023

SELL
$314.42 - $351.91 $134,571 - $150,617
-428 Reduced 50.0%
428 $151,000
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $208,460 - $233,316
663 Added 343.52%
856 $50,000
Q1 2023

May 10, 2023

SELL
$283.23 - $323.1 $118,106 - $134,732
-417 Reduced 68.36%
193 $61,000
Q1 2023

Apr 26, 2023

BUY
$283.23 - $323.1 $113,008 - $128,916
399 Added 189.1%
610 $49,000
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $15,145 - $17,038
53 Added 33.54%
211 $61,000
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $34,984 - $41,233
158 New
158 $41,000
Q4 2021

Feb 11, 2022

SELL
$177.01 - $223.45 $42,128 - $53,181
-238 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $43,170 - $48,311
238 New
238 $43,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Vestor Capital, LLC Portfolio

Follow Vestor Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestor Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vestor Capital, LLC with notifications on news.